Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Inclusion Criteria: * Elevated LDL-C of \>3.0 mmol/L and \<5.7 mmol/L * Fasting triglyceride concentration ≤2.8 mmol/L * Body weight \>60.0 kg; body mass index (BMI) between 19.00 kg/m2 and \<35.00 kg/m2 * Adequate blood counts, liver and renal function * May not received any lipid lowering drug/agent within the 30 days prior to the screening * Non-smokers for at least 3 months * Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control * Males agree to use appropriate contraception * Willing and able to comply with protocol-required visit schedule and visit requirements and provide written informed consent Exclusion Criteria: * Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection * Multiple drug allergies or know sensitivity to oligonucleotide * History of drug abuse and/or alcohol abuse * Receiving an investigational agent within 3 months prior to study drug administration * Subjects with safety laboratory test results deemed clinical significant by the Investigator; * Received prescription drugs within 4 weeks of first dosing * Subjects who have donated more than 500 mL of blood within the 3 months prior to ALN-PCS02 or placebo administration; * Received megadose vitamin therapy or dietary supplements within 4 weeks prior to screening * Subjects who have used prescription drugs within 4 weeks of first dosing * Considered unfit for the study by the Principal Investigator * Employee or family member of the sponsor or the clinical study site personnel